Unicycive Therapeutics, Inc. Profile Avatar - Palmy Investing

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for …

Biotechnology
US, Los Altos [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of UNCY's Analysis
CIK: 1766140 CUSIP: 90466Y103 ISIN: US90466Y1038 LEI: - UEI: -
Secondary Listings
UNCY has no secondary listings inside our databases.